Charles Larsen

Partner McDermott Will & Schulte

Published by this author:

Patents

The UPC and life sciences three years in: medtech’s early success, pharma/biotech’s selective bet

McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks

Charles Larsen, September 29 2026